Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 2/20 | 0.42 |
| ▸ | EDNRA | P25101 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263686 | 0.86 | ATM (0.46) | PSIP1ATMHSD17B2EDNRBEDNRA | |
| SCHEMBL4251866 | 0.85 | PLCG1 (0.56) | ATMHSD17B2EDNRBEDNRAMMP2 | |
| SCHEMBL17263850 | 0.84 | PSIP1 (0.68) | PSIP1BRD4ALDH1A1GAAMEN1 | |
| SCHEMBL1710715 | 0.83 | ATM (0.41) | PSIP1ATMHSD17B2EDNRBEDNRA | |
| SCHEMBL29068356 | 0.82 | PLCG1 (0.44) | ATMHSD17B2EDNRBEDNRAMMP2 | |
| SCHEMBL6726327 | 0.82 | ATM (0.45) | ATMHSD17B2EDNRBEDNRAMMP2 | |
| SCHEMBL3600024 | 0.82 | ATM (0.49) | ATMHSD17B2EDNRBEDNRAMMP2 | |
| SCHEMBL17364184 | 0.82 | ATM (0.45) | ATMHSD17B2MMP2BRD4ALDH1A1 | |
| SCHEMBL30633557 | 0.80 | POLB (0.49) | ATMHSD17B2BRD4ALDH1A1EGFR | |
| SCHEMBL17699828 | 0.79 | ATM (0.43) | ATMHSD17B2EDNRBEDNRAMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3774775-B1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| CN-110799490-B | 3-arylpropionamide compound and method for producing 3-arylpropionate compound | 住友化学株式会社 | 2023-05-02 | — | — | CN | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-11505543-B2 | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2022-11-22 | — | — | US | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3838903-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| US-11028056-B2 | Method for producing 3-arylpropionamide compound and 3-arylpropionic acid ester compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-06-08 | — | — | US | disclosed |
| EP-3774775-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| WO-2009086130-A1 | IMIDAZO [1,2-B] PYRIDAZINE COMPOUNDS AS MODULATORS OF LIVER X RECEPTORS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086138-A1 | BENZIMIDAZOLE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086129-A1 | PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086123-A1 | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
| CN-101448826-A | Heteroaryl substituted pyrrolo [2 ] as janus kinase inhibitors | INCYTE CORP (US) | 2009-06-03 | — | — | CN | disclosed |
| WO-2009020683-A2 | QUINAZOLINE COMPOUNDS | WYETH (US) | 2009-02-12 | — | — | WO | disclosed |
| EP-1966202-A1 | HETEROARYL SUBSTITUTED PYRROLOÝ2,3-B¨PYRIDINES AND PYRROLOÝ2,3-B¨PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | PSIP1 3289/4885ATM 1090/4885HSD17B2 3129/4885 |
| US-11505543-B2 | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication | EIF2AK2, CCNI, IRF3 | PSIP1 1368/4885ATM 3277/4885HSD17B2 2080/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | PSIP1 3027/4885ATM 1045/4885HSD17B2 2701/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | PSIP1 3289/4885ATM 1090/4885HSD17B2 3129/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | PSIP1 3289/4885ATM 1090/4885HSD17B2 3129/4885 |
| US-11028056-B2 | Method for producing 3-arylpropionamide compound and 3-arylpropionic acid ester compound | AADAC, DDT, NAT1 | PSIP1 3276/4885ATM 579/4885HSD17B2 4225/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | PSIP1 3289/4885ATM 1090/4885HSD17B2 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.